Abstract
Recent advances in designing peptide ligands for therapeutic targets are making peptides an attractive alternative to small molecules and proteins. It is now common to see peptides developed with affinities comparable to antibodies and specificities much better than small molecules or antibodies. This is especially true in the case of tumor targeting cytotoxic drugs or targeted diagnostics where peptides can be used as a delivery vehicle for drugs or diagnostics. Moreover, lessons learned from nature in understanding peptide ligands are proving to be useful in designing better antibodies and small molecule therapeutics.
Keywords: c-MET, HMPs, heterodimer, peptide, VEGFR-2, antibody, small molecule, targeted drugs
Current Pharmaceutical Design
Title: Designer Peptides: Learning from Nature
Volume: 15 Issue: 6
Author(s): A. Shrivastava, A. D. Nunn and M. F. Tweedle
Affiliation:
Keywords: c-MET, HMPs, heterodimer, peptide, VEGFR-2, antibody, small molecule, targeted drugs
Abstract: Recent advances in designing peptide ligands for therapeutic targets are making peptides an attractive alternative to small molecules and proteins. It is now common to see peptides developed with affinities comparable to antibodies and specificities much better than small molecules or antibodies. This is especially true in the case of tumor targeting cytotoxic drugs or targeted diagnostics where peptides can be used as a delivery vehicle for drugs or diagnostics. Moreover, lessons learned from nature in understanding peptide ligands are proving to be useful in designing better antibodies and small molecule therapeutics.
Export Options
About this article
Cite this article as:
Shrivastava A., Nunn D. A. and Tweedle F. M., Designer Peptides: Learning from Nature, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315620
DOI https://dx.doi.org/10.2174/138161209787315620 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Neovascularization in Hematological Malignancies: Biologic and Clinical Implications)
Current Angiogenesis (Discontinued) Melanoma
Current Cancer Therapy Reviews Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Pharmacological Properties of Thalidomide and its Analogues
Recent Patents on Inflammation & Allergy Drug Discovery Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials
Anti-Cancer Agents in Medicinal Chemistry Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Pharmacokinetics, Organ Toxicity and Antitumor Activity of Docetaxel Loaded in Folate Targeted Cholesterol Based Micelles
Current Drug Delivery CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas
Current Cancer Drug Targets Advances in the Management of Malignant Hemopathies: The Role of Statins
Recent Patents on DNA & Gene Sequences Camptothecins and Lung Cancer: Improved Delivery Systems by Aerosol
Current Cancer Drug Targets Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry